CeriBellCBLL
Recorded

CeriBell 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration42 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Thank you for standing by. My name is Jordan, and I will be your operator this day. Welcome to the CeriBell Q3 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw a question, press star one again. As a reminder, each participant is limited to one question per query, and you can requeue if you would like to ask another question. I would now like to turn the call over to Brian Johnston to start today's conference.

Brian JohnstonInvestor Relations

You may begin. Good afternoon, and thank you all for participating in today's call.

Brian JohnstonInvestor Relations

Joining me from CeriBell are Jane Chao, Co-founder and Chief Executive Officer, and Scott Blumberg, Chief Financial Officer. Earlier today, CeriBell issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of the press release is available on the investor relations section of the company's website. Before we begin, I would like to remind you that management will make remarks during this call that include forward-looking statements within the meaning of federal securities laws, and that these are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements.

Brian JohnstonInvestor Relations

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors section of our public filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed with the SEC on February 24, 2026, and quarterly report on Form 10-Q for the quarter ended September 30, 2026. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 3, 2026. CeriBell disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise.

Brian JohnstonInvestor Relations

With that, I will turn the call over to Jane.

Jane ChaoCo-founder and CEO

Good afternoon, and thank you for joining us for our third quarter 2026 earnings call. Q3 marked another strong quarter for CeriBell, as we delivered revenue of $29.3 million, growing approximately 30% year-over-year. Underlying growth was driven by success across both core revenue drivers, adoption by more accounts and deeper penetration within our install base. In Q3, we increased our account base by a record 35 hospitals to a total of 747 active accounts. This is a reflection of the continued maturation and strong performance of our account acquisition team. We maintain a robust pipeline of unlaunched accounts that we expect to drive sustained growth in the coming quarters. Headband utilization also reached a new record in Q3. Year-over-year usage per account grew at a double-digit rate, the highest we have seen since our IPO.

Jane ChaoCo-founder and CEO

This builds on our Q2 momentum and reflects the execution of our playbook: provider engagement, department expansion, and patient population protocolization. Department expansion is particularly accelerating. We have expanded into more departments year to date in 2026 than we did during the entirety of 2025, and we expect to continue the pace. These results collectively serve to further validate our core seizure business as a durable growth engine. Overlaying our core strategy, we are also making progress against several key initiatives we have launched this year to supplement our organic growth. First, we are seeing positive signs out of our newly established strategic account management team. Through top-down engagement with regional health systems, we believe this team will drive new avenues for account growth. While these opportunities unlock at inherently longer sales cycles, we continue to see larger deals advancing through our sales funnel.

Jane ChaoCo-founder and CEO

Second, our VA and DoD strategy remains a growth driver, with strong engagement with both government health systems. In Q3, we secured a commitment to further expand within VA, which should have a positive impact on active accounts and revenue growth in the coming quarters. Finally, interest in our neonatal product remains strong, with ongoing pipeline development and activation of NICUs within new and existing accounts. With strong signal across each of these key 2026 initiatives, we are well-positioned to drive continued revenue growth as we move into 2027. Now, I would like to turn our attention to delirium, our next major growth opportunity. Earlier this week, we announced the launch of our delirium monitoring solution. We recently concluded a commercial pilot evaluating clinical utility and adoption among customers already using our seizure platform.

Jane ChaoCo-founder and CEO

Six months later, I am excited to report that the pilot has shown meaningful impact, both in optimizing patient care and in validating our delirium monitoring solution as a new revenue stream. The encouraging results we shared last quarter have continued, now across a larger number of accounts. Customers reported improvements in clinical decision-making and positive user experiences. In many cases, our solution is enabling long-term monitoring for the first time, which is especially notable in difficult-to-assess patients. To illuminate this clinical value, I would like to share a patient story that highlights the unique benefits offered by our delirium monitoring solution. In this case, a woman in her early 30s with sepsis was admitted to the ICU at a 150-bed community hospital and primary stroke center. The patient was not at neurological baseline, so the care team placed a CeriBell headband to evaluate potential causes.

Jane ChaoCo-founder and CEO

The system returned a seizure-negative result and a delirium-positive result, giving the team immediate objective direction to focus on delirium management. Before adopting CeriBell's delirium monitoring solution, this site's delirium assessments were inconsistent and rarely part of routine discussion. Here, the result prompted nurses, physicians, and pharmacists to review potential contributors together. In a septic patient, antibiotics was not always questioned. This time, the team identified cefepime, a commonly used antibiotic with neurotoxicity, as a potential contributor to patient's delirium, and elected to transition the patient to a different antibiotic drug. Besides the initial delirium detection, CeriBell also enabled continuous monitoring after the antibiotic adjustment. The delirium trend began to decrease. By day three, the patient was no longer delirium positive.

Jane ChaoCo-founder and CEO

The team believes the objective diagnosis and trend monitoring gave the team a clear reason to revisit the infection treatment decision and the information necessary to determine that their strategy was effective in resolving delirium. Clinicians at other sites have reported similar experiences, validating our value proposition and driving repeat usage. CeriBell helps care team to recognize delirium rapidly while opening management pathways, from medication reviews to non-drug interventions. As these experiences accumulate, we expect adoption to broaden and usage to become entrenched. Within the pilot, the clinical utility of our system has directly translated into commercial impact. We are seeing a material increase in headband utilization by established customers who subsequently launched our delirium monitoring solution. Future growth is likely to result from patient population expansion, significant clinical utility from simultaneous monitoring for delirium and seizure, and engagement with customers.

Jane ChaoCo-founder and CEO

This impact has proven durable, with our earliest customers having had at least 120 days of usage following launch. Importantly, the usage impact was seen before our NTAP went into effect on October 1, suggesting that clinical utility is a primary driver. As we continued refining our launch practices, we have also seen even larger usage impact in more recently launched accounts. Based on these results, we believe that reducing barriers to adoption will enable us to drive meaningful commercial impact. As we move into commercial launch, we are offering our delirium monitoring solution as a software upgrade to CeriBell customers at no incremental increase to the subscription fee. Instead, we are requiring interested customers to partner with us through program commitments that we believe are critical to maximize clinical utility and sustained usage.

Jane ChaoCo-founder and CEO

For example, we ask our customer to ensure we can train more than 80% of their nurses and physicians during launch processes and align on KPIs for delirium monitoring and management. We are also working with customers to ensure that they have sufficient recorder capacity to handle the increased patient volume and potentially longer monitoring durations for delirium. This approach ensures that our customers are set up for success with high-quality launches. Providing the product without an incremental subscription cost largely avoids lengthy sales and contracting processes that could slow adoption. That said, the launch process that we have seen drive impact requires thoughtful execution over time. Implementing such a disruptive technology involves customers evolving their practice and working closely with our team. We expect that many accounts will adopt our delirium monitoring solution quickly, but broad-scale conversion will occur over time.

Jane ChaoCo-founder and CEO

We believe this approach will ultimately maximize sustained revenue impact from increased clinical usage, the key metric for revenue contribution from our delirium monitoring solution. We will continue to track the utilization impact as we move from pilot into full launch. As part of our 2027 financial guidance, we plan to provide a more granular perspective on anticipated revenue impact associated with this greenfield market opportunity. Importantly, our strategy will be executed by our existing sales organization, provide a greater leverage of our commercial infrastructure. We look forward to providing updates on these elements of our delirium monitoring solution's impact on our financial performance as well. Our product development strategy rests on two core pillars: enhancing our algorithms to deliver better clinical insights and innovating our hardware platforms to support the algorithms.

Jane ChaoCo-founder and CEO

Our delirium monitoring solution is an excellent example of the first pillar, as it expands our reach into new patient populations. We also continue to develop other algorithms that increase the clinical utility of our product for our physician customers. Two such examples are recently FDA 510(k)-cleared algorithms for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis. Quantitative EEG, or qEEG, extends three functionalities: alpha-delta ratio, relative alpha trending, and burst suppression monitoring. Clinicians commonly use these trends when managing complex neurological conditions to help assess brain distress, reduced blood flow, or excessive sedation. However, these outputs remain largely inaccessible for the bedside clinicians despite their clinical relevance. Our algorithm will change that. We offer our customers greater insights into patients' brain activity. This materially strengthens our value proposition for both bedside users and neurologists. These features will be released via a cloud-based software update next year.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day